In contrast, patient cohorts from Japan report a higher prevalence, with over one-third of JDM patients testing positive for anti-MDA5 antibodies, and more than half of those developing RP-ILD [2, 5]. This evidence concerns the gene IFIH1 and juvenile dermatomyositis.